Abstract

In this issue of Blood, Amengual et al report the results of a single-institution dose-escalation phase 1 study of pralatrexate plus romidepsin for patients with relapsed/refractory non-Hodgkin lymphoma. This combination resulted in a very high response rate in patients with previously treated peripheral T-cell lymphoma (PTCL) 1 .

Original languageEnglish (US)
Pages (from-to)375-376
Number of pages2
JournalBlood
Volume131
Issue number4
DOIs
StatePublished - Jan 25 2018

Fingerprint

Peripheral T-Cell Lymphoma
T-cells
Refractory materials
Blood
Non-Hodgkin's Lymphoma
10-propargyl-10-deazaaminopterin
romidepsin

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Peripheral T-cell lymphoma : Novel backbone. / Vose, Julie Marie.

In: Blood, Vol. 131, No. 4, 25.01.2018, p. 375-376.

Research output: Contribution to journalReview article

Vose, Julie Marie. / Peripheral T-cell lymphoma : Novel backbone. In: Blood. 2018 ; Vol. 131, No. 4. pp. 375-376.
@article{40ed183da9dd4bc2b5cbcddbb09e446e,
title = "Peripheral T-cell lymphoma: Novel backbone",
abstract = "In this issue of Blood, Amengual et al report the results of a single-institution dose-escalation phase 1 study of pralatrexate plus romidepsin for patients with relapsed/refractory non-Hodgkin lymphoma. This combination resulted in a very high response rate in patients with previously treated peripheral T-cell lymphoma (PTCL) 1 .",
author = "Vose, {Julie Marie}",
year = "2018",
month = "1",
day = "25",
doi = "10.1182/blood-2017-11-817734",
language = "English (US)",
volume = "131",
pages = "375--376",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Peripheral T-cell lymphoma

T2 - Novel backbone

AU - Vose, Julie Marie

PY - 2018/1/25

Y1 - 2018/1/25

N2 - In this issue of Blood, Amengual et al report the results of a single-institution dose-escalation phase 1 study of pralatrexate plus romidepsin for patients with relapsed/refractory non-Hodgkin lymphoma. This combination resulted in a very high response rate in patients with previously treated peripheral T-cell lymphoma (PTCL) 1 .

AB - In this issue of Blood, Amengual et al report the results of a single-institution dose-escalation phase 1 study of pralatrexate plus romidepsin for patients with relapsed/refractory non-Hodgkin lymphoma. This combination resulted in a very high response rate in patients with previously treated peripheral T-cell lymphoma (PTCL) 1 .

UR - http://www.scopus.com/inward/record.url?scp=85041051359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041051359&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-11-817734

DO - 10.1182/blood-2017-11-817734

M3 - Review article

C2 - 29371206

AN - SCOPUS:85041051359

VL - 131

SP - 375

EP - 376

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -